Is Aquestive Therapeutics, Inc. (AQST) halal? Doubtful. Based on AAOIFI screening, Aquestive Therapeutics, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 70/100 (Grade: B+).

Aquestive Therapeutics, Inc.

AQST: Is Aquestive Therapeutics, Inc. Halal?

Doubtful

Aquestive Therapeutics, Inc.

NASDAQHealthcareUS

$3.93

-1.75%

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Sector: Healthcare 路 Industry: Drug Manufacturers - Specialty & Generic

Why This Stock Is Doubtful

  • Interest-bearing deposits are 26.0% of market cap, only 4.0 points below the 30% limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 18, 2026
B+

Good

Good compliance with minor concerns

70Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Passed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap9.7% / 30.0%

Compliance History

  1. Doubtfulnow

    since Jun 2026

  2. Not Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 18, 2026Fiscal: Q1 2026Source: EDGAR

Purify Your AQST Dividends

Calculate your purification amount for AQST dividends based on AAOIFI standards.

Financial Overview

Market Cap

390.3M

Price

$3.93

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

More Healthcare Stocks

JNJ

Johnson & Johnson

A

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

A

PFE

Pfizer Inc.

F

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+
Free 路 No credit card required

Track AQST and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started FreeBrowse Screener
10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Aquestive Therapeutics, Inc. (AQST) halal to invest in?
Aquestive Therapeutics, Inc. (AQST) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.
Why did Aquestive Therapeutics, Inc. get a B+ compliance rating?
Aquestive Therapeutics, Inc. (AQST) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 9.7% (limit 30%); interest-bearing deposits of 26.0% (limit 30%); prohibited income of 0.00% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Aquestive Therapeutics, Inc.'s Shariah verdict?
Aquestive Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Aquestive Therapeutics, Inc. re-screened for Shariah compliance?
Aquestive Therapeutics, Inc. (AQST) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 18, 2026.

Screened according to AAOIFI Standard No. 21 路 For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.